Aanyone working on novel drug delivery systems?
538746
yup.\n\nWell, "working" is a strong word.
50936
For once, a person willing to do his? her? own research, only asking for a link! :)\n\nhttp://www.drugs.com/pill_identification.html
1019519
Pharmaceutical companies
564264
Basically, it is tagging the substance to be delivered to an incredibly tiny particle of gold; usually, there is an antibody (or other targeting substance) attached to the gold particle as well, to target a specific cell type or cellular structure.  It is the antibody that does the targeting; the gold nanoparticle is but the (essentially passive) tool used to carry the targeting molecule and the drug molecule.\n\nIt's one of the developing technologies--it's far from being routine, yet, last I heard.
431177
They havent yet. Not in the usefull sense. However, I know scientists are sucessfull in creating components for nanobots. They've created ultra small engines, switches, transistors, wires, etc. The tecnological hurdle as I understand it is that 'connecting' these devices are really tricky.
1085517
I think you may have meant Watson Pharmaceuticals. If this is what you intended click the link below to go to their site.\n\nSincerely,\nTerry
1073888
Hey, you're really close to my office. Try Adelphia. They're right around the corner in SM. Off of Olympic & Stewart.
672953
Go to pubmed (www.pubmed.com) and put in the words you are interested in-this is an example of a 30 second search.\n\n1:  Prego C, Torres D, Alonso MJ. \n The potential of chitosan for the oral administration of peptides.\nExpert Opin Drug Deliv. 2005 Sep;2(5):843-54. Review. \nPMID: 16296782 [PubMed - indexed for MEDLINE]\n\n2:  Yi H, Wu LQ, Bentley WE, Ghodssi R, Rubloff GW, Culver JN, Payne GF. \n Biofabrication with chitosan.\nBiomacromolecules. 2005 Nov-Dec;6(6):2881-94. Review. \nPMID: 16283704 [PubMed - indexed for MEDLINE]\n\n3:  Ni Mhurchu C, Dunshea-Mooij CA, Bennett D, Rodgers A. \n Chitosan for overweight or obesity.\nCochrane Database Syst Rev. 2005 Jul 20;(3):CD003892. Review. \nPMID: 16034912 [PubMed - indexed for MEDLINE]\n\n4:  Di Martino A, Sittinger M, Risbud MV. \n Chitosan: a versatile biopolymer for orthopaedic tissue-engineering.\nBiomaterials. 2005 Oct;26(30):5983-90. Review. \nPMID: 15894370 [PubMed - indexed for MEDLINE]\n\n5:  Il'ina AV, Varlamov VP. \n [Chitosan-based polyelectrolyte complexes: a review]\nPrikl Biokhim Mikrobiol. 2005 Jan-Feb;41(1):9-16. Review. Russian. \nPMID: 15810726 [PubMed - indexed for MEDLINE]\n\n6:  Prabaharan M, Mano JF. \n Chitosan-based particles as controlled drug delivery systems.\nDrug Deliv. 2005 Jan-Feb;12(1):41-57. Review. \nPMID: 15801720 [PubMed - indexed for MEDLINE]\n\n7:  Shahidi F, Abuzaytoun R. \n Chitin, chitosan, and co-products: chemistry, production, applications, and\nhealth effects.\nAdv Food Nutr Res. 2005;49:93-135. Review. No abstract available. \nPMID: 15797344 [PubMed - indexed for MEDLINE]\n\n8:  Kato Y, Onishi H, Machida Y. \n Contribution of chitosan and its derivatives to cancer chemotherapy.\nIn Vivo. 2005 Jan-Feb;19(1):301-10. Review. \nPMID: 15796190 [PubMed - indexed for MEDLINE]\n\n9:  Wang LH, Wu GL, Cheng YY. \n [Applications of chitosan and its derivatives in pharmaceutical industry of\nChinese medicine]\nZhongguo Zhong Yao Za Zhi. 2004 Apr;29(4):289-92. Review. Chinese. \nPMID: 15706858 [PubMed - indexed for MEDLINE]\n\n10:  Mhurchu CN, Dunshea-Mooij C, Bennett D, Rodgers A. \n Effect of chitosan on weight loss in overweight and obese individuals: a\nsystematic review of randomized controlled trials.\nObes Rev. 2005 Feb;6(1):35-42. Review. \nPMID: 15655037 [PubMed - indexed for MEDLINE]
263550
Never heard of it, but that sounds interesting...\n\n\nYou probably can do a search of it on the patent office website.
767910
it would be considered as alternate medicine and subsequently western standard of medical research may not have been completed on this plant, sounds interesting though, good luck
697543
development of drugs using biochemistry\nunderstanding of organic processes\nenergy production\nmany others
1088906
My best guess would be Genentech. Try looking it up on the web. I'm pretty sure they're one of the top.
825828
When was the last time any big moneymaking disease was cured?  In this advanced scientific age you would think quite often.  I don't have an exact answer, but I can't think of anything recent.  It would not be profitable for the pharmaceutical companies.  So instead, we just get better ways to control our disease and we live longer so that they can make even more money from us.  Will it ever happen?  Probably.  Will it happen in our lifetime?  Doubtful.
438096
http://www.pharmer.org/node/2102
609200
Good luck getting a pharmaceutical company to do anything close to charitable! They are in business for the PROFITS!
888180
Sorry, but Arcoxia is still undergoing trials & the results are still mixed.  Here's one of the latest links from Merck regarding the drug.  Good luck.
1006883
NanoSys\nFounded by CEO Larry Bock, one of the biggest heavyweights in the small tech world, and who has funded and launched other successful biotech startups, Nanosys is Boston-based company that develops nanotechnology-enabled systems, with applications in molecular sensing, optoelectronics, and nanoelectronics. Bock's track record of launching over a dozen life science companies, and its IP, has helped Nanosys attract VC capital during one of the toughest eras for financing--last February the company announced $15 million in Series B financing from five top-tier firms. The company is relucant to disclose what it considers to be its smoking gun to enter the market, but has made considerable progress in nanometer transistors, which will thus enable a new generation of computer chips. \n\n\nHybrid Plastics \nA U.S. Air Force Research Laboratory spin-off, Hybrid Plastics made its mark in the industry for the development of a revolutionary plastics technology derived from sand which is extremely strong, efficient, and does not cause air pollution during production. 205 companies buy trademarked nanostructured chemicals from the now privately held company, which is a recipient of the 2000 CalTIP award. Hybrid Plastics, which was able to grow in its early stages through the assistance of government R&D funding, now sell materials for research and development. The company's products are utilized for a variety of clients--optical, computing and electronics, and beauty corporations. \n\n\nChemat Technology \nConsidered survivors of government-funded research and development, Chemat became a profitable business in 2000 (half of that attributed to customer sales), a decade since the sol-gel solution company was founded. Prior to that, Chemat's R&D Division was successful in completing nearly one hundred contracts for government agencies and industry clients. Its mission is the creation and commercialization of sol-gel based advanced materials and technologies, for its own use and to provide its clients with technologies they can use to create leading-edge products using advanced materials. \n\nLuxtera\nA Caltech-UCLA spinoff, Luxtera was founded by two leaders in the field of nano photonics--Eli Yablonovitch, the inventor of the photonic crystal, and Dr. Axel Scherer, who has led pioneering work in nanoscale fabrication. Receiving $7 million in an A round last February, Luxtera's product is based on Caltech developments in the field of nanophotonics. This technology\nis based upon optical structures which are an order of magnitude smaller than those traditionally used in integrated optical devices. This technology could thus reduce the cost of optical-electronic transitions and optoelectronic systems. \n\n\nBroadley-James\nBroadley-James has the kind of business dilemma that most companies would gladly take on--supplying a heavy demand for its product. Thanks to a distribution decision made by Beckman Instruments back in the late 1960's, the company was able to penetrate the pH sensor market and become a leading manufacturer over the next three decades. It has positioned itself favorably by entering the biotech-pharmaceutical market, an industry that has increased production drastically (and thus created strong market demand). In order to reach its next stepping stone, Broadley-James was awarded a Larta-facilitated CalTIP grant last year, and will use those funds, as well as SBIR and UC grant support, to work towards improving and creating a new generation of pH sensors. The funds, still being budgeted for the project, will go towards marketing and promotion, as well as production engineering. \n\nNano Devices\nIn 2001, Nanodevices was one of the Santa Barbara companies Larta awarded CalTIP funding. This helped the company to complete a 2002 launch date, and NanoDevices is now shipping its Active Probe™ technology on the Digital Instruments, Veeco Metrology NanoScope® IV. In a move calculated to increase the grow